Related references
Note: Only part of the references are listed.Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors
Kyle A. Edgar et al.
CANCER RESEARCH (2010)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
PI(3)King Apart PTEN's Role in Cancer
Siyuan Zhang et al.
CLINICAL CANCER RESEARCH (2010)
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer
Leonard Da Silva et al.
BREAST CANCER RESEARCH (2010)
Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
Bryan T. Hennessy et al.
CANCER RESEARCH (2009)
Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
Evelyn Yao et al.
CLINICAL CANCER RESEARCH (2009)
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Klaus P. Hoeflich et al.
CLINICAL CANCER RESEARCH (2009)
Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Xiaolan Hu et al.
MOLECULAR CANCER RESEARCH (2009)
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Florence I. Raynaud et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Knockin of mutant PIK3CA activates multiple oncogenic pathways
John P. Gustin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
MicroRNAs Differentially Regulated by Akt Isoforms Control EMT and Stem Cell Renewal in Cancer Cells
Dimitrios Iliopoulos et al.
SCIENCE SIGNALING (2009)
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype
David Sarrió et al.
CANCER RESEARCH (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Epithelial mesenchymal transition traits in human breast cancer cell lines
T. Blick et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
Stuart Thomson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Class IPI3K in oncogenic cellular transformation
L. Zhao et al.
ONCOGENE (2008)
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
Federica Di Nicolantonio et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras-mediated transformation
Hiroyuki Konishi et al.
CANCER RESEARCH (2007)
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases
Florence I. Raynaud et al.
CANCER RESEARCH (2007)
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression
Paraic A. Kenny et al.
MOLECULAR ONCOLOGY (2007)
Three-dimensional culture models of normal and malignant breast epithelial cells
Genee Y. Lee et al.
NATURE METHODS (2007)
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
Elizabeth Buck et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA
Jung-Sik Kim et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition
Haihe Wang et al.
CANCER RESEARCH (2007)
Characterization of a protein kinase B inhibitor in vitro and in insulin-treated liver cells
Lisa Logie et al.
DIABETES (2007)
Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for snail, slug, and E47 factors in epithelial-mesenchymal transition
Gerna Moreno-Bueno et al.
CANCER RESEARCH (2006)
Gene expression profiling of breast cell lines identifies potential new basal markers
E Charafe-Jauffret et al.
ONCOGENE (2006)
Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2
H Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
PIK3CA mutations in breast cancer are associated with poor outcome
SY Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition
HY Irie et al.
JOURNAL OF CELL BIOLOGY (2005)
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients
RL Yauch et al.
CLINICAL CANCER RESEARCH (2005)
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells
SJ Isakoff et al.
CANCER RESEARCH (2005)
Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT
M Yoeli-Lerner et al.
MOLECULAR CELL (2005)
Epithelial-mesenchymal transition in development and cancer:: role of phosphatidylinositol 3′ kinase/AKT pathways
L Larue et al.
ONCOGENE (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
LH Saal et al.
CANCER RESEARCH (2005)
Discovery of 2,3,5-trisubstituted pyridine derivatives as potent AM Akt1 and Akt2 dual inhibitors
ZJ Zhao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
SY Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
PI3K-Akt pathway: Its functions and alterations in human cancer
M Osaki et al.
APOPTOSIS (2004)
Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner
J Debnath et al.
JOURNAL OF CELL BIOLOGY (2003)
Tumour-cell invasion and migration: Diversity and escape mechanisms
P Friedl et al.
NATURE REVIEWS CANCER (2003)
Serine/threonine phosphorylation of IRS-1 triggers its degradation - Possible regulation by tyrosine phosphorylation
TM Pederson et al.
DIABETES (2001)
Share Paper
